Diagnostic Application of FISH to Hematological Malignancies

References

• Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• An International System for Human Cytogenetic Nomenclature (1995). F. Mitelman. S. Karger, Basel 1995
   Google Scholar
• Speicher M.R., Ballard S.G., Ward D.C. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat. Genet. 1996; 12: 368–375
   PubMed Web of Science ®Google Scholar
• Schrock E., du Manoir S., Veldman T., et al. Multicolor spectral karyotyping of human chromosomes. Science 1996; 273: 494–497
   PubMed Web of Science ®Google Scholar
• Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinicrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y., Daley G.Q., Mes-Masson A.-M., et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212–214
   PubMed Web of Science ®Google Scholar
• Faderal S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Tkachuk D.C., Westbrook C.A., Andreeff M., et al. Detection of BCR-ABL fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990; 259: 559–562
   Google Scholar
• Dewald G.W., Wyatt W.A., Juneau A.L., et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR-ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar
• Sinclair P.B., Nacheva E.P., Leversha M., et al. Large deletions of the t(9;22) breakpoint are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–744
   PubMed Web of Science ®Google Scholar
• Cohen N., Rozenfeld-Granot G., Hardan I., et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet. Cytogenet. 2001; 128: 114–119
   PubMed Web of Science ®Google Scholar
• Mrozek K., Heinonen K., de la Chapelle A., et al. Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol. 1997; 24: 17–31
   PubMed Web of Science ®Google Scholar
• Nucifora G., Rowley J.D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1–14
   PubMed Web of Science ®Google Scholar
• Wang Q., Stacey T., Binder M., et al. Disruption of Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl Acad. Sci. USA 1996; 93: 3444–3449
   PubMed Web of Science ®Google Scholar
• Grimwade D., Biondi A., Mozziconacci M.-J., et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): result of the European Working Party. Blood 2000; 96: 1297–1308
   PubMed Web of Science ®Google Scholar
• He L.-Z., Guidez F., Triboli C., et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat. Genet. 1998; 18: 126–135
   PubMed Web of Science ®Google Scholar
• Liu P.P., Castilla L.H., Adya N. The leukemogenic function of the inv(16) fusion gene CBFB-MYH11. Transcription Factors, K. Ravid, J.D. Licht. Wiley-Liss. 2001; 379–391
   Google Scholar
• Haferlach T., Winkemann M., Loffler H., et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining with fluorescence in situ hybridization. Blood 1996; 87: 2459–2463
   PubMed Web of Science ®Google Scholar
• Ziemen-van der Poel S., McCabe N.R., Gill H.J., et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias [published erratum appear in Proc. Natl Acad. Sci. USA 1992, 89, 4220]. Proc. Natl Acad. Sci. USA 1991; 88: 10735–10739
   PubMed Web of Science ®Google Scholar
• Rowley J.D. The role of chromosomal translocations in leukemogenesis. Semin. Hematol. 1999; 36: 59–72
   PubMed Web of Science ®Google Scholar
• Van den Berghe H., Michaux L. 5q−, twenty-five years later: a synopsis. Cancer Genet. Cytogenet. 1997; 94: 1–7
   PubMed Web of Science ®Google Scholar
• Horrigan S.K., Arbieva Z.H., Xie H.Y., et al. Delineation of minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95: 2372–2377
   PubMed Web of Science ®Google Scholar
• Najfeld, V.; Montella, L.; Scalise, A.; et al. Exploring polycythemia vera with FISH: additional cryptic 9p is the most frequent abnormality detected. Br. J. Haematol. 2002, 1–9.
   Google Scholar
• Greenberg P., Cox C., Le Beau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Rubinitz J.E., Pui C.H., Downing J.R. The role of TEL fusion genes in pediatric leukemia. Leukemia 1999; 13: 6–13
   PubMed Web of Science ®Google Scholar
• Appelbaum F.R. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin. Hematol. 1999; 36: 401–410
   PubMed Web of Science ®Google Scholar
• Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Liu Y., Hermanson M., Grander D., et al. 13q deletions in lymphoid malignancies. Blood 1995; 86: 1911–1915
   PubMed Web of Science ®Google Scholar
• Perez-Simon J.A., Garcia-Sanz R., Tabernaro M.D., et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366–3371
   PubMed Web of Science ®Google Scholar
• Desikan R., Barlogie B., Saweyer J., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010
   PubMed Web of Science ®Google Scholar
• Stammatopoulos K., Kosmas C., Belessi C., et al. Molecular insights into the immunopathogenesis of follicular lymphoma. Blood 2000; 96: 808–822
   PubMedGoogle Scholar
• Siebert R., Mathiesen P., Harder S., et al. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood 1998; 91: 984–990
   PubMed Web of Science ®Google Scholar
• Ye H.B. BCL6 in the pathogenesis of non-Hodgkin's lymphoma. Cancer Investig. 2000; 18: 356–365
   PubMed Web of Science ®Google Scholar
• Siebert R., Matthisen P., Harder S., et al. Application of interphase cytogenetics for detection of t(11;14)(q13;q32) in mantle cell lymphoma. Ann. Oncol. 1998; 9: 519–526
   PubMed Web of Science ®Google Scholar
• Dierlamm J., Wlodarska I., Michauc L., et al. Genetic abnormalities in marginal zone B-cell lymphoma. Hematol. Oncol. 2000; 18: 1–13
   PubMed Web of Science ®Google Scholar
• Morris S.W., Kirstein M., Valentine M., et al. Fusion of a kinase gene ALK to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284
   PubMed Web of Science ®Google Scholar
• Benharroch D., Meguerin-Bedoyan Z., Lamant L., et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076–2084
   PubMed Web of Science ®Google Scholar